When Weight Comes Back After Bariatric Surgery: What a GLP-1 Adds

Weight coming back after bariatric surgery is common, it is not a moral failure, and it now has a pharmacological answer with evidence behind it. Pooling 19 studies of people who had regained weight or never lost enough after surgery, adding a GLP-1 produced a mean further loss of 7.02 kg.^[1] A second review put the pooled effect at a Cohen’s d of 0.470 — moderate.^[2] One detail is missing from almost every summary of this evidence, and it changes how you should read the numbers.

Why weight returns after surgery

Two distinct things get conflated. Insufficient weight loss means the operation never produced the expected result. Weight regain means it did, and then some of it came back. They have different causes and the literature increasingly treats them separately, though they respond to the same intervention.

Neither is unusual. Surgery changes the anatomy and much of the hormonal signaling, but it does not switch off the biology that defends a body weight, and over years that biology reasserts itself in a substantial minority of people. Anyone who has been told this is a matter of willpower has been told something the surgical literature does not support.

What adding a GLP-1 achieved

A Cohen’s d of 0.470 is worth translating. It is a moderate effect, not a dramatic one — noticeably better than nothing and not comparable to what the original operation did. The second review’s own framing is that these drugs “show promise and deserve additional research” as part of standard care after surgery, which is a fair reading of a moderate pooled effect.^[2]

The dose almost nobody mentions

Here is the detail that should change how you read every number above. In the included studies, the highest doses used were liraglutide 3 mg daily and semaglutide 1 mg once weekly.^[1]

1 mg weekly is the diabetes dose. The weight-management dose is 2.4 mg.

So this evidence was generated at well under half the semaglutide dose someone would now be prescribed for exactly this problem. That cuts two ways, and honesty requires both. It may mean the real-world effect at current doses is larger than 7 kg. It also means nobody has actually measured that, and the confident figure circulating is from a dose most of these patients are no longer given.

Questions worth asking first

• Which problem is it? Insufficient loss and regain are different, and a surgeon who distinguishes them is thinking about causes rather than reaching for the same answer twice.
• Has anything anatomical been ruled out? A dilated pouch or a widened outlet is a surgical finding with a surgical answer, and a drug will not fix it.
• How will the gastrointestinal effects interact with the anatomy you now have? Nausea and vomiting are the class’s commonest effects and an altered stomach changes how they are experienced.
• Who is managing this? Bariatric follow-up and telehealth prescribing frequently do not talk to each other, and this is a case where they should.

Our constipation guide and side-effect timeline cover the gastrointestinal side, and the bariatric overlap cheat sheet covers which operation interacts with what.

One thing this evidence does not address at all: what happens when the drug stops. The withdrawal trials in people who never had surgery are unambiguous that most of the weight returns — see what happens when you stop — and nobody has run that trial in post-surgical patients. If the drug is being added because weight came back once, the plan for stopping it deserves asking about at the start.

Two different failures, and only one has a randomized trial

Surgery can disappoint in two distinct ways, and they are routinely discussed as one thing. Someone can lose a great deal and then regain it. Or they can never lose enough in the first place — a suboptimal initial response. The evidence differs sharply between them.

For the second, there is now a proper trial. BARI-STEP randomized 70 adults who were at least a year past gastric bypass or sleeve gastrectomy and had lost less than 20% of their weight from surgery, to semaglutide 2.4 mg or placebo, double-blind, for 68 weeks. Everyone also received a lifestyle intervention with a 500-calorie daily deficit.^[4]

Adverse events matched the known profile of the drug with no new concerns specific to operated anatomy. There were eight serious adverse events and one suspected unexpected serious adverse reaction, which the published abstract does not describe, and no treatment-related deaths.

For regain specifically, the evidence is weaker

A 2026 cohort followed 34 people with recurrent weight gain after bariatric surgery or an endoscopic procedure through 24 weeks of tirzepatide at 2.5 to 10 mg weekly. Mean total body weight loss was 18.1% ± 5.6% (P < 0.0001).^[3]